Seagen Inc. (SGEN): Price and Financial Metrics
SGEN Price/Volume Stats
| Current price | $228.74 | 52-week high | $228.96 |
| Prev. close | $228.90 | 52-week low | $123.77 |
| Day low | $228.74 | Volume | 20,075,400 |
| Day high | $228.96 | Avg. volume | 1,478,439 |
| 50-day MA | $215.13 | Dividend yield | N/A |
| 200-day MA | $202.50 | Market Cap | 42.93B |
SGEN Stock Price Chart Interactive Chart >
Seagen Inc. (SGEN) Company Bio
Seagen Inc. is an American biotechnology company focused on developing and commercializing innovative, empowered monoclonal antibody-based therapies for the treatment of cancer. The company, headquartered in Bothell, Washington (a suburb of Seattle), is the industry leader in antibody-drug conjugates or ADCs, a technology designed to harness the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. Antibody-drug conjugates are intended to spare non-targeted cells and thus reduce many of the toxic effects of traditional chemotherapy, while potentially enhancing antitumor activity. (Source:Wikipedia)
Latest SGEN News From Around the Web
Below are the latest news stories about SEAGEN INC that investors may wish to consider to help them evaluate SGEN as an investment opportunity.
PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) Approved by FDA as the First and Only ADC Plus PD-1 to Treat Advanced Bladder CancerAstellas Pharma Inc. (TSE:4503, President and CEO: Naoki Okamura, "Astellas") and Pfizer Inc. (NYSE: PFE) today announced that on December 15, 2023 the U.S. Food and Drug Administration (FDA) has approved PADCEV® (enfortumab vedotin-ejfv, an antibody-drug conjugate [ADC]) with KEYTRUDA® (pembrolizumab, a PD-1 inhibitor) for the treatment of adult patients with locally advanced or metastatic urothelial cancer (la/mUC). This combination is the first approved to offer an alternative to platinum-con |
3 Stocks That Are About to Get Absolutely CrushedThese are a few different companies that are experiencing difficult times and that are expected to keep falling. |
3 Sleepy Stocks Ready to Wake up in 2024Strong projected earnings growth makes these three stocks strong candidates for exceptional growth in 2024. |
Big Pharma: Why the drug industry faces a 3-front battle with the FTC, Medicare, and the White HouseThe Biden administration is increasingly focused on finding ways to lower drug prices, putting the drug industry in a three-way battle to defend its ecosystem. |
We're Interested To See How Seagen (NASDAQ:SGEN) Uses Its Cash Hoard To GrowWe can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining... |
SGEN Price Returns
| 1-mo | N/A |
| 3-mo | N/A |
| 6-mo | 6.06% |
| 1-year | 12.53% |
| 3-year | 55.36% |
| 5-year | 221.76% |
| YTD | N/A |
| 2023 | 0.00% |
| 2022 | -16.88% |
| 2021 | -11.73% |
| 2020 | 53.28% |
| 2019 | 101.66% |
Continue Researching SGEN
Want to do more research on Seattle Genetics Inc's stock and its price? Try the links below:Seattle Genetics Inc (SGEN) Stock Price | Nasdaq
Seattle Genetics Inc (SGEN) Stock Quote, History and News - Yahoo Finance
Seattle Genetics Inc (SGEN) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...